Testosterone supplementation may be effective for the treatment of hypogonadism in men with type 2 diabetes mellitus (T2DM), but the evidence from randomized controlled trials (RCTs) is inconclusive. We aimed to systematically summarize results from intervention studies and assess the effects of testosterone supplementation therapy (TST) on lipid metabolism in RCTs of hypogonadal men with T2DM by meta-analysis. PubMed, Embase, and Cochrane Library databases were searched for studies reporting the effect of TST on lipid metabolism in hypogonadal men with T2DM until December 31, 2016. Seven RCTs from 252 trials, enrolling a total of 612 patients in the experimental and control groups with a mean age of 58.5 years, were included in this study. The pooled results of the meta-analysis demonstrated that TST significantly decreased TC and TG levels in hypogonadal men with T2DM compared with the control group, with mean differences (MDs) of -6.44 (95% CI: -11.82 to -1.06; I = 28%; p = 0.02) and -27.94 (95% CI: -52.33 to -3.54; I = 76%; p = 0.02). Subgroup analyses revealed that the heterogeneity (I = 76%) of TG originated from different economic regions, in which economic development, genetic and environmental factors, and dietary habits affect lipid metabolism of human, with a decrease (I = 45%) in developed countries. Additionally, subgroup analyses showed that TST increased HDL-C level in developing countries compared with the control group (MD = 2.79; 95% CI: 0.73 to 4.86; I = 0%; p = 0.008), but there was no improvement in developed countries (MD = 1.02; 95% CI: -4.55 to 6.60; I = 91%; p = 0.72). However, LDL-C levels were not improved consistently. Because the relationship between lipid metabolism and atherosclerosis is unequivocal, TST, which ameliorates lipid metabolism, may decrease the morbidity and mortality of cardiovascular disease in hypogonadal men with T2DM by preventing atherogenesis.
BACKGROUND Type 1 diabetes mellitus (T1DM) is the most common chronic autoimmune disease among children and adolescents. Telemedicine is the use of medical information exchanged from one site to another via electronic communications to improve the health of patients. It has been widely used in the field of chronic disease management and brings the gospel to patients with T1DM. OBJECTIVE This study aims to systematically review the evidence on the effectiveness of telemedicine intervention compared with usual care on glycemic control among children and adolescents with T1DM. METHODS In this systematic review and meta-analysis, we searched PubMed, Cochrane Library, Embase, Web of Science (all databases), and CINAHL Complete from database inception to May 2023. We included randomized controlled trials that evaluated the effectiveness of a telemedicine intervention on glycemic control in children and adolescents with T1DM. Two independent reviewers performed the study selection and data extraction. Study quality was assessed using the Cochrane risk-of-bias tool 2.0. Our primary outcome was HbA1c levels. Secondary outcomes were quality of life (QOL), self-monitoring of blood glucose (SMBG), the incidence of hypoglycemia, and cost-effectiveness. The random effects model was used for this meta-analysis. RESULTS In total, 20 randomized controlled trials (1704 participants from 12 countries) were included in the meta-analysis. Only one study was at high risk of bias. Compared to usual care, telemedicine was found to reduce HbA1c by 0.21% (95% CI –0.33 to –0.09; p<.001; I2=33.9%). There was an improvement in SMBG (MD 0.54; 95% CI –0.72 to 1.80; p=.045; I2=67.8%) and the incidence of hypoglycemia (MD –0.15; 95% CI –0.57 to 0.27; p=.017; I2=70.7%), although this was not statistically significant. Moreover, telemedicine also had no convincing effect on the DQOLY (Impact of diabetes p=59; Worries about diabetes: p=.71; Satisfaction with diabetes: p=.68) and the N-QOL (p=.054). Subgroup analyses revealed that the effect of telemedicine of on HbA1c appeared to be greater in studies involving children (MD –0.41; 95% CI –0.62 to –0.20; p<.001), in studies that lasted less than six months (MD –0.32; 95% CI –0.48 to –0.17; p<.001), in studies where providers used smartphone applications to communicate with patients (MD –0.36; 95% CI –0.52 to –0.21; p<.001), and in studies with medication dose adjustment (MD –0.25; 95% CI –0.37 to –0.12; p<.001). CONCLUSIONS This study has shown that telemedicine is an efficacious and safe treatment approach for children and adolescents with T1DM, leading to reduced HbA1c levels for children and adolescents with T1DM. Further research is needed to validate the effectiveness of telemedicine on the quality of life of children and adolescents and to measure the cost-effectiveness of telemedicine applications among children and adolescents with T1DM. CLINICALTRIAL PROSPERO International Prospective Register of Systematic Reviews CRD42023423882; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=423882
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.